Cancer Research

#Cancer research #Clinical trials #Oncology #OneOncology #Partnership #START Center for Cancer Research (START)

Strategic partnership to launch new clinical trial sites

The START Center for Cancer Research (START) and OneOncology has announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN, California), The Center for Cancer and Blood Disorders (CCBD, Texas), and Astera Cancer Care (New Jersey). This arrangement builds on… Read More

#Cancer Research #News

#Colorectal cancer #Funding #Oncology #Start-ups #University of Arizona #University of Dundee

Start-up receives $4m towards ‘one-shot’ cancer drug

A drug discovery company co-founded by researchers at the University of Dundee and the University of Arizona has received $4 million in venture funding.  Branch Therapeutics, founded in November 2024, is a preclinical stage company seeking to develop drugs that are orally bioavailable, well-tolerated, and can treat… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

#Cancer research #Cancer vaccines #Collaboration #Immunology / Virology & Vaccines #NHS Cancer Vaccine Launch Pad #Scancell Holdings

In Conversation With: Phil L’Huillier, Scancell

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Phil L’Huillier, CEO of… Read More

#Cancer Research #News

Liver cancer
#Moderna #mRNA #Oncology #Phase I trial #Solid tumours

Pan-tumour antigen therapy candidate enters the clinic

The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours.  The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik. Read More

#Cancer Research #News

#Cancer drug targets #Cancer research #Oncology #Proteins #Surfaceome

Shining a light on the surfaceome – the new frontier in cancer drug discovery

Reece Armstrong examines the advances being made in identifying cell surface proteins and what this means for cancer drug discovery. There have been some landmark FDA approvals in recent years – but not everyone has picked up on the significance of its decision to green-light Merus’ lung and pancreatic cancer… Read More

#Cancer Research #Exclusive Content

Cancer research in laboratory
#Investment #Oncology #Prostate cancer #University of Queensland

$1.25 million support for advanced prostate cancer drug

A $1.25 million investment is driving the development of a new treatment for advanced and therapy-resistant prostate cancer at The University of Queensland.  Based on research by Professor Greg Monteith from UQ’s School of Pharmacy and Pharmaceutical Sciences, the drug (QED-203) is being developed by the Queensland… Read More

#Cancer Research #Editor's Choice #News

Gastrointestinal tract
#Cell and gene therapy #Cell therapy #CRISPR #Gastrointestinal #Gene editing #Oncology

CRISPR TIL therapy shows early success in GI cancers

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.   The results, published in Lancet Oncology, show encouraging signs of safety and potential… Read More

#Cancer Research #Editor's Choice #News

Cancer research
#AACR #AACR 2025 #Cancer research #Opinion

Expert reflections from AACR 2025

DDW’s Megan Thomas hears from industry experts Daniel Veres, Turbine’s Chief Scientific Officer & Co-Founder, as well as Ryan Jacobs, Business Development Manager at Astoriom, about AACR 2025. MT: What do you consider to be the key trends in cancer research? Daniel Veres: Key trends in cancer research include a… Read More

#Cancer Research #Exclusive Content #Opinion

CAR-T cells attacking a cancer cell
#Cancer research #CAR-T #Cell and gene therapy #Leucid Bio #Solid tumours

First patient dosed in CAR-T therapy trial for solid tumours

Leucid Bio has dosed the first patient in the Phase I AERIAL trial evaluating the safety and clinical activity of LEU011 in patients with refractory solid tumours. Initiation of the AERIAL trial follows the successful first close of the Series A1 financing of £7.2 ($9.51) million in February 2025, co-led… Read More

#Cancer Research #News

Indonesian and Scottish flags
#Cancer Research UK #Collaboration #Indonesia #Oncology #Scotland

Indonesia-Scotland cancer research partnership signed

The Ministry of Health of the Republic of Indonesia and the CRUK Scotland Institute have entered into a landmark partnership to advance cancer research, build capacity in cancer care, and support evidence-based health policies through the signing of a Memorandum of Understanding (MoU).  Dr Susanti Susanti, an… Read More

#Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Cancer research #Solid tumours #SOTIO

The challenges in solid tumour targeting with bispecific ADCs

Czech biotechnology company, SOTIO, recently started preclinical development of its first two bispecific antibody drug conjugates (ADCs), which it says are “just the beginning” of what it has in store for its next-generation ADC pipeline. DDW’s Megan Thomas speaks with SOTIO’s Chief Scientific Officer, Martin Steegmaier, about the company’s pipeline. Read More

#Cancer Research #Exclusive Content

Human adenovirus
#biological engineering #CAR-T #Cell and gene therapy #Cell therapy #EsoBiotec #In vivo

Revolutionising cancer treatment with viral vectors

CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer… Read More

#Cancer Research #Exclusive Content

Antibody drug conjugate
#AACR #Antibody drug conjugate (ADC) #Oncology #Solid tumours #SOTIO

ADCs show best-in-class potential for treating solid tumours

SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models.  The data shared at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL supports… Read More

#Cancer Research #News

Liver cancer
#Macrophages #Oncology #Phase I trial #Pheast Therapeutics #Solid tumours

First patient receives anti-CD24 macrophage checkpoint inhibitor

Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours.  The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours.  The study’s primary objectives… Read More

#Cancer Research #News #Trending News

#Artificial intelligence (AI) #Cancer research #Data management #Diversity #Oncology #Quantum computing

Opportunities and challenges in oncology

DDW Editor Reece Armstrong takes a look at some of the recent activity in cancer research and examines where the biggest opportunities are in oncology.  In January this year, researchers from the University of Toronto (UoT) and Insilico Medicine published a paper detailing how quantum computing combined with generative… Read More

#Cancer Research #Exclusive Content #Trends & Analysis